|
Name |
Cyclopentanone, 3,3,4-trimethyl-4-(4-methylphenyl)-
|
Molecular Formula | C15H20O | |
IUPAC Name* |
3,3,4-trimethyl-4-(4-methylphenyl)cyclopentan-1-one
|
|
SMILES |
CC1=CC=C(C=C1)C2(CC(=O)CC2(C)C)C
|
|
InChI |
InChI=1S/C15H20O/c1-11-5-7-12(8-6-11)15(4)10-13(16)9-14(15,2)3/h5-8H,9-10H2,1-4H3
|
|
InChIKey |
MTWLTRIBMFLOIL-UHFFFAOYSA-N
|
|
Synonyms |
25090-79-3; Cyclopentanone, 3,3,4-trimethyl-4-(4-methylphenyl)-; 3,3,4-Trimethyl-4-(4-methylphenyl)cyclopentanone; SCHEMBL2946642; DTXSID50342624; 3,3,4-trimethyl-4-(p-tolyl)-cyclopentan-1-one; 3,3,4-Trimethyl-4-(4-methylphenyl)cyclopentanone #
|
|
CAS | 25090-79-3 | |
PubChem CID | 583402 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 216.32 | ALogp: | 3.5 |
HBD: | 0 | HBA: | 1 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 17.1 | Aromatic Rings: | 2 |
Heavy Atoms: | 16 | QED Weighted: | 0.682 |
Caco-2 Permeability: | -4.753 | MDCK Permeability: | 0.00002070 |
Pgp-inhibitor: | 0.966 | Pgp-substrate: | 0.004 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.004 |
30% Bioavailability (F30%): | 0.003 |
Blood-Brain-Barrier Penetration (BBB): | 0.826 | Plasma Protein Binding (PPB): | 79.42% |
Volume Distribution (VD): | 1.477 | Fu: | 24.76% |
CYP1A2-inhibitor: | 0.271 | CYP1A2-substrate: | 0.883 |
CYP2C19-inhibitor: | 0.813 | CYP2C19-substrate: | 0.948 |
CYP2C9-inhibitor: | 0.561 | CYP2C9-substrate: | 0.826 |
CYP2D6-inhibitor: | 0.047 | CYP2D6-substrate: | 0.859 |
CYP3A4-inhibitor: | 0.465 | CYP3A4-substrate: | 0.554 |
Clearance (CL): | 9.217 | Half-life (T1/2): | 0.317 |
hERG Blockers: | 0.061 | Human Hepatotoxicity (H-HT): | 0.357 |
Drug-inuced Liver Injury (DILI): | 0.171 | AMES Toxicity: | 0.02 |
Rat Oral Acute Toxicity: | 0.091 | Maximum Recommended Daily Dose: | 0.036 |
Skin Sensitization: | 0.121 | Carcinogencity: | 0.136 |
Eye Corrosion: | 0.152 | Eye Irritation: | 0.733 |
Respiratory Toxicity: | 0.168 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000772 | 0.615 | D0M6DO | 0.286 | ||||
ENC001317 | 0.593 | D08EOD | 0.273 | ||||
ENC000233 | 0.354 | D08KVZ | 0.270 | ||||
ENC000199 | 0.346 | D0X0WU | 0.270 | ||||
ENC000457 | 0.340 | D0N0RU | 0.270 | ||||
ENC000221 | 0.333 | D02WCI | 0.258 | ||||
ENC000086 | 0.327 | D09BHB | 0.250 | ||||
ENC000146 | 0.302 | D0T1WN | 0.244 | ||||
ENC000796 | 0.292 | D06OIV | 0.243 | ||||
ENC002065 | 0.284 | D06GIP | 0.241 |